

Electronic Acknowledgement Receipt

EFS ID:	9747700
Application Number:	10567057
International Application Number:	
Confirmation Number:	4884
Title of Invention:	Novel use of quinolone antibiotics
First Named Inventor/Applicant Name:	Gert Daube
Customer Number:	71285
Filer:	Jessica Jacqueline Monachello
Filer Authorized By:	
Attorney Docket Number:	LEA 36807
Receipt Date:	28-MAR-2011
Filing Date:	26-JUN-2006
Time Stamp:	10:39:46
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$2100
RAM confirmation Number	11361
Deposit Account	504260
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		oa36807.pdf	1163358	yes	7
			ab500bf4b70bbb6957dbc4da064096d5abcd7a91		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment Submitted/Entered with Filing of CPA/RCE		1	1	
	Claims		2	2	
	Applicant Arguments/Remarks Made in an Amendment		3	7	
Warnings:					
Information:					
2	Amendment Submitted/Entered with Filing of CPA/RCE	rce36807.pdf	622939	no	3
			d2eeafea1e3aa2827b386e2a6d73c6a2367edb3c		
Warnings:					
Information:					
3	Extension of Time	pet36807.pdf	134093	no	1
			1d1a356260928ecc44ee3c7f61c0153e945891f0		
Warnings:					
Information:					
4	Rule 130, 131 or 132 Affidavits	decl36807.pdf	14673003	no	57
			4208c7f1313cece0af14a619edee59abd21ba61		
Warnings:					
Information:					
5	Applicant Arguments/Remarks Made in an Amendment	resp36807.pdf	532216	no	2
			cb8a68bc064732a40d44ee7006376b132d6bc981		
Warnings:					
Information:					
6	Information Disclosure Statement (IDS) Filed (SB/08)	suppids36807.pdf	930488	no	4
			4eb0a820e2a1d1203e3346427e8e31192bc96de5		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					

7	NPL Documents	gendron.pdf	3985956 c1ca016c9f4541afa2d14b6360f57b9a33a838c4	no	10
Warnings:					
Information:					
8	Fee Worksheet (PTO-875)	fee-info.pdf	33303 524a98212f5522541e3507daecbdad7133946667	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			22075356		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					